Related Experiment Video
Updated: Aug 13, 2025
Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
Published on: May 16, 2020
Development and validation of non-invasive models in predicting advanced fibrosis of choledochal cyst
Suyun Chen1,2, Tong Yin1,2, Long Li3,4,5
1Capital Institute of Pediatrics-Peking University Teaching Hospital, Beijing, China.
Purpose:
Patients with choledochal cyst (CDC) develop liver fibrosis, especially advanced fibrosis without prompt surgery. This study validated the aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and Fibrosis-4 index (FIB-4) and constructed a model for predicting advanced fibrosis in pediatric CDCs.
Methods:
Between January 2020 and March 2022, 330 CDCs (advanced fibrosis: 34, Ludwig staging 3-4; non-advanced fibrosis: 296, Ludwig staging 0-2) were reviewed. APRI and FIB-4 were validated. The area under the receiver operating characteristic (AUROC) curve was used to assess discrimination. Relevant variables were analyzed by backward stepwise logistic regression. Enhanced bootstrap method was used for internal verification with 1000 samples.
Results:
The AUROCs of APRI and FIB-4 were 0.761 (0.673-0.850) and 0.561 (0.455-0.667). AST to prealbumin ratio (APAR), was constructed with an AUROC of 0.776 (0.693-0.860). The AUROCs of APAR + APRI and APAR + FIB-4 were 0.791 (0.713-0.869) and 0.782 (0.699-0.865). No significant differences were noted in the AUROCs of the indices or their combinations. APAR and APRI could be used together to reduce missed diagnosis rate. The risk of advanced fibrosis varied from different APAR and APRI scores.
Conclusion:
Both APAR and APRI were indispensable to identify CDC patients at high risk of advanced fibrosis.
